Stress-hormone pathway probe (POMC joining peptide, mouse fragment 115-134)
A small protein fragment from the pituitary gland's master hormone precursor, used in labs to study how the stress hormone cortisol is triggered; research tool only, not a drug.
- Class
- Endogenous peptide fragment (POMC-derived)
- Status
- No approved therapeutic status identified
- Main caveat
- Detected peptide sequence only. No characterized bioactivity, mechanism, or therapeutic evidence is attached to this card.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
The pro-opiomelanocortin [115-134] peptide — also called the POMC joining peptide (JP) — is a 20-residue fragment that sits inside the much larger precursor hormone POMC. POMC is produced mainly in the pituitary gland and serves as the master precursor for several better-known hormones: ACTH, α-MSH, and β-endorphin. The joining peptide is the short connecting region that links the N-terminal γ-MSH-containing fragment to ACTH within the precursor chain. This particular version is from mouse (Mus musculus); the human joining peptide is 30 residues and differs in sequence. For most of its research history the JP was treated as an uncharacterised by-product of POMC processing — a spacer left over once the "important" hormones were cleaved out. That picture has since become more nuanced.
The stored 20-letter sequence (RPVKVYPNVAENESAEAFPL) represents the bare backbone; in processed pituitary tissue the C-terminal leucine is likely amidated (–NH₂ cap), a modification not visible in the raw sequence that is characteristic of the mature JP (Bertagna and colleagues 1988).
History
POMC was first fully described as a single precursor encoding both ACTH and β-LPH following cDNA cloning in the late 1970s. Once the precursor structure was mapped, the joining peptide was identified by sequencing the region between the N-terminal fragment and ACTH. Early work in the 1980s — including a radioimmunoassay study by Bertagna and colleagues (1988) — showed that human JP is secreted from the pituitary largely as a C-terminally amidated homodimer, probably held together by a disulfide bond at its single cysteine residue, and circulates at molar concentrations comparable to ACTH itself. Despite this evidence that JP is genuinely secreted — not simply degraded after cleavage — no receptor or signalling function was identified, and the peptide remained one of POMC's least-studied products.
The mouse JP sequence was characterised through peptidomic studies of mouse pituitary. Che and colleagues (2005), working with wild-type and Cpefat/fat mice (a model with inactive carboxypeptidase E), used stable isotope labelling and mass spectrometry to quantify POMC-derived fragments in pituitary extracts and found multiple JP-related species among the products (Che and colleagues, Journal of Mass Spectrometry, 2005).
In 2023, Hiroshima and colleagues at Kindai University reported the first characterised biological activity for the joining peptide: concentration-dependent cell adhesion via integrin-mediated binding. The porcine JP carries an RGD motif (the classical integrin recognition sequence), while the human JP has an RSD variant; both promoted cell adhesion in HEK 293T assays, with binding abolished by EDTA but not heparin — a profile consistent with divalent-cation-dependent integrin engagement (Hiroshima and colleagues, Molecules, 2023).
What it does
The joining peptide is a processing by-product released when PC1 (proprotein convertase 1) cleaves POMC in anterior pituitary corticotrophs. It is generated alongside ACTH, β-LPH, and the N-terminal γ-MSH-containing fragment every time the stress-response hormone ACTH is produced. Unlike ACTH — which binds the MC2R receptor on adrenal cortex cells to drive cortisol production — the joining peptide does not appear to activate melanocortin receptors. Its recently identified activity is cell adhesion: the peptide binds integrin proteins on cell surfaces in a concentration-dependent manner (Hiroshima and colleagues 2023).
In a research context, POMC [115-134] is used as a probe peptide to study MC2R ligand selectivity. MC2R is the only melanocortin receptor that responds exclusively to full-length ACTH and is unable to bind any of the MSH peptides (Cai and colleagues 2016). Because the joining peptide directly flanks ACTH in the precursor but lacks the His-Phe-Arg-Trp core sequence that MSH-family peptides share, it helps researchers delineate which structural features of ACTH are required for MC2R engagement — and which are not.
Evidence
- Human: No clinical trials have been conducted with the isolated joining peptide. Immunoreactive JP has been detected in human pituitary tissue, in ACTH-secreting pituitary and non-pituitary tumours, and in plasma from patients with ACTH hypersecretory syndromes, at concentrations equimolar to other POMC-derived peptides (Bertagna and colleagues 1988).
- Animal: Mouse pituitary JP and related fragments have been quantified by stable-isotope peptidomics in wild-type and Cpefat/fat mice (Che and colleagues 2005). No registered trials on ClinicalTrials.gov for the POMC joining peptide or its mouse variant.
- In vitro: Synthetic joining peptides from porcine and human POMC promoted concentration-dependent cell adhesion in HEK 293T cells via integrin-mediated, EDTA-sensitive binding. The human RSD-containing variant and the porcine RGD-containing variant both showed activity, confirming the motif as functionally relevant (Hiroshima and colleagues 2023).
Known effects
- Cell adhesion (in vitro, integrin-mediated) — Preclinical; demonstrated with synthetic JP peptides in cell culture (Hiroshima and colleagues 2023)
- MC2R probe activity (research use) — The peptide is used to assess MC2R binding specificity by serving as an ACTH-flanking negative control that lacks the MC2R-activating core sequence
- Pituitary co-secretion with ACTH — Physiological; JP is co-released equimolarly with ACTH during corticotroph stimulation (Bertagna and colleagues 1988)
Safety signals
No toxicological or clinical safety data are available for the isolated POMC [115-134] joining peptide. It has been studied only as a synthetic research peptide in cell-based assays and in peptidomic characterisation of mouse pituitary tissue.
Regulatory status
- US: Not approved by the FDA; not a pharmaceutical agent. Research peptide only.
- EU: Not evaluated by EMA.
- WADA: Not listed on the WADA prohibited list as an isolated compound.
Mechanism
POMC is processed in anterior pituitary corticotrophs primarily by PC1, which cleaves at paired basic residue sites (Lys-Arg or Arg-Arg) to release the N-terminal fragment, joining peptide, ACTH, and β-LPH as distinct products. The joining peptide sits at the POMC [~115-134] position in the mouse precursor, immediately N-terminal to ACTH. In the intermediate pituitary lobe, where both PC1 and PC2 are active, further cleavage of ACTH yields α-MSH and CLIP; the JP itself is not further cleaved in this pathway.
The melanocortin receptor most relevant to this fragment's research context is MC2R, the dedicated ACTH receptor expressed predominantly in the adrenal cortex. MC2R is unique among the five melanocortin receptors in that it responds only to ACTH and requires the accessory protein MRAP for membrane trafficking (Cai and colleagues 2016). The joining peptide, lacking the His-Phe-Arg-Trp pharmacophore present in all MSH-family agonists, does not activate MC2R or any other melanocortin receptor, making it a useful structural reference for receptor selectivity studies.
The cell adhesion activity characterised by Hiroshima and colleagues (2023) operates through a separate, integrin-dependent pathway. The EDTA sensitivity of the binding (EDTA chelates Mg²⁺ and Mn²⁺ required for integrin activation) and its insensitivity to heparin (ruling out heparan-sulfate proteoglycan involvement) are consistent with integrin engagement. The physiological significance of this integrin-binding activity in vivo remains an open question.
Related peptides
- ACTH — The immediately C-terminal neighbour of JP in the POMC precursor; the primary MC2R agonist and cortisol-stimulating hormone
- α-MSH — N-terminal fragment of ACTH produced by further processing in the intermediate pituitary; MC1R and MC3R–MC5R agonist; shares no activity with JP
- See also the melanocortin receptor system overview: Cai and colleagues (Current Protein & Peptide Science, 2016) provides context on how the five MCR subtypes differ in ligand selectivity
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does adding the natural chemical cap (amide) to the end of this peptide turn it from an inactive fragment into a real receptor activator?
If amidation is the key, many published results showing JP as biologically inert would need to be revisited. More importantly, it could open the door to a new class of adrenal-targeting peptide drugs based on a naturally occurring human sequence, which tend to have better safety profiles than synthetic compounds.
Does this peptide need to pair up with a copy of itself before it can activate a receptor and produce a biological effect?
If the dimer is the active form, this would explain decades of confusing results around the joining peptide's function. It would also suggest that the pituitary uses an unusual two-molecule signaling mechanism that could potentially be targeted with drugs that either promote or break up the dimer, relevant to pituitary adenoma treatment.
Does the shorter mouse form of this peptide miss important contacts with the receptor that the longer human form makes?
If mouse and human versions of this peptide behave differently, it would mean that many stress-response experiments done in mice may not predict what happens in people. This finding would push researchers to test the human version of the peptide directly, potentially correcting flawed assumptions about how the human stress axis is regulated.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.7379341721534729 | boltz-2 |
| ranking score | 0.7841787934303284 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10637,
sequence = {RPVKVYPNVAENESAEAFPL},
target = {mc2r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}